.png?bc=ffffff&h=60&la=en&w=250&hash=D4E558BE41F5D9E7E7CC458758B16488B3D292F9){kind=logo}
Coronavirus (COVID-19) Update
AmerisourceBergen and our global businesses are highly engaged during the ongoing spread of the novel COVID-19 “Coronavirus."
US Bioservices now dispenses XOSPATA® (gilteritinib)
June 17, 2020
XOSPATA® is an oral once-daily kinase inhibitor indicated for the treatment of adult patients who have relapsed or refractory acute myeloid leukemia (AML) with a FLT3 mutation as detected by an FDA-approved test.